ALX Oncology
Hank Stern has held various leadership positions in the biopharmaceutical industry, with a focus on CMC activities for the development, manufacturing, and distribution of biological drug substances and products. With a strong background in fermentation sciences and biochemical engineering, combined with a Master of Business Administration degree, Hank has extensive experience in leading international technology transfer activities, process development, formulation development, technology transfer, and clinical manufacturing. Hank's expertise lies in driving project strategy, goals, and objectives while resolving issues effectively.
This person is not in any offices
ALX Oncology
ALX Oncology is a publicly traded, clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system.